NASDAQ:CLVS

Clovis Oncology Stock Forecast, Price & News

$4.83
-0.02 (-0.41 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.78
$4.94
50-Day Range
$4.76
$6.54
52-Week Range
$4.08
$11.10
Volume2.06 million shs
Average Volume4.47 million shs
Market Capitalization$505.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
30 days | 90 days | 365 days | Advanced Chart
Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.


Clovis Oncology logo

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

627th out of 2,223 stocks

Pharmaceutical Preparations Industry

320th out of 869 stocks

Analyst Opinion: 3.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

Is Clovis Oncology a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Clovis Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View analyst ratings for Clovis Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Clovis Oncology?

Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clovis Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Clovis Oncology
.

How can I listen to Clovis Oncology's earnings call?

Clovis Oncology will be holding an earnings conference call on Wednesday, August 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.72) by $0.08. The biopharmaceutical company earned $38.05 million during the quarter, compared to analysts' expectations of $44.84 million.
View Clovis Oncology's earnings history
.

How has Clovis Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLVS shares have decreased by 21.7% and is now trading at $4.83.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CLVS?

4 equities research analysts have issued 12-month price targets for Clovis Oncology's shares. Their forecasts range from $3.00 to $12.00. On average, they anticipate Clovis Oncology's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price.
View analysts' price targets for Clovis Oncology
or view top-rated stocks among Wall Street analysts.

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64) (LinkedIn Profile)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.21%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen.
View institutional ownership trends for Clovis Oncology
.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen.
View insider buying and selling activity for Clovis Oncology
or or view top insider-buying stocks.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $4.83.

How much money does Clovis Oncology make?

Clovis Oncology has a market capitalization of $505.07 million and generates $164.52 million in revenue each year. The biopharmaceutical company earns $-369,210,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

Where are Clovis Oncology's headquarters?

Clovis Oncology is headquartered at 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.